SPY072
Rheumatoid Arthritis (RA)
Key Facts
About Spyre Therapeutics
Spyre Therapeutics is pioneering a novel approach to treating IBD and rheumatological diseases by developing engineered antibodies designed for prolonged activity and convenient, infrequent dosing. Its core strategy involves targeting well-validated pathways—α4β7, TL1A, and IL-23—both as monotherapies and in innovative combinations, with the goal of achieving deeper remission for patients. The company is advancing a robust pipeline through its Phase 2 SKYLINE-UC trial and has built a leadership team with extensive experience in drug development and commercialization. Spyre's vision is to overcome the limitations of current therapies, such as low remission rates and frequent injections, by delivering superior efficacy and improved patient compliance.
View full company profileAbout Spyre Therapeutics
Spyre Therapeutics is pioneering a novel approach to treating IBD and rheumatological diseases by developing engineered antibodies designed for prolonged activity and convenient, infrequent dosing. Its core strategy involves targeting well-validated pathways—α4β7, TL1A, and IL-23—both as monotherapies and in innovative combinations, with the goal of achieving deeper remission for patients. The company is advancing a robust pipeline through its Phase 2 SKYLINE-UC trial and has built a leadership team with extensive experience in drug development and commercialization. Spyre's vision is to overcome the limitations of current therapies, such as low remission rates and frequent injections, by delivering superior efficacy and improved patient compliance.
View full company profileAbout Spyre Therapeutics
Spyre Therapeutics is pioneering a novel approach to treating IBD and rheumatological diseases by developing engineered antibodies designed for prolonged activity and convenient, infrequent dosing. Its core strategy involves targeting well-validated pathways—α4β7, TL1A, and IL-23—both as monotherapies and in innovative combinations, with the goal of achieving deeper remission for patients. The company is advancing a robust pipeline through its Phase 2 SKYLINE-UC trial and has built a leadership team with extensive experience in drug development and commercialization. Spyre's vision is to overcome the limitations of current therapies, such as low remission rates and frequent injections, by delivering superior efficacy and improved patient compliance.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis (RA) Drugs
| Drug | Company | Phase |
|---|---|---|
| Rosnilimab | AnaptysBio | Phase 1 |
| CLN-978 | Cullinan Therapeutics | Phase 1 |
| Telitacicept | Vor Biopharma | Marketed |
| ABO21009 | AboleIIs Pharma | Phase 1 |